- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05257512
Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
A Phase I/II, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Antitumor Activity of SY-3505 Capsule in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Study Overview
Detailed Description
The study consists of two parts:
Part 1: Dose-escalation and dose-expansion in patients with advanced ALK-positive NSCLC, including 9 SY-3505 dose levels.
Dose-escalation study phase is designed to determine the dose-limiting toxicity (DLT) according to a 3+3 design and recommended phase II dose (RP2D) and to characterize the safety, tolerability, and pharmacokinetics (PK) profile of SY-3505. Other dose regimens may be explored based on the analysis of emerging PK and safety data. At this study phase, SY-3505 administered orally once daily (QD) in 28-day treatment cycles to adult patients with ALK-positive NSCLC. Dose-expansion study is designed to evaluate the antitumor activity (ORR, DCR and DoR) of SY-3505 at selected doses in ALK-positive NSCLC patients who have received at least 1 prior ALK TKI therapy.
Part 2: Phase 2 study to evaluate the efficacy of SY-3505.
This phase is designed to determine the antitumor activity (ORR, DCR, DoR, PFS and OS), safety, and PK of SY-3505 at RP2D in ALK-positive NSCLC patients who have received alectinib only or ≥2 prior ALK TKIs.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Recruiting
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Yuankai Shi, MD
- Phone Number: 86-10-87788293
- Email: syuankai@cicams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years at the time of screening.
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Estimated Life expectancy ≥ 12 weeks.
- Must have either at least one measurable lesion with no prior local treatment or measurable lesions with definite progression (Bone metastases alone were not accepted) after local treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Dose-escalation phase: patients must have histological or cytological confirmed ALK-positive advanced NSCLC. Dose-expansion phase: patients must have histological or cytological confirmed ALK-positive advanced NSCLC and progressed after at least one prior line of ALK TKI therapy. Phase II: patients must have histological or cytological confirmed ALK-positive advanced NSCLC and progressed after only alectinib or ≥2 prior ALK TKIs treatment. The pathological report requires either positivity for ALK gene expression determined by fluorescence in-situ hybridization (FISH) assay, immunohistochemistry (IHC), reverse transcription-polymerase chain reaction (RT-PCR), next-generation sequencing (NGS) or other identified methods from previous reports and provide tissue for ALK retest if possible or providing tissue for ALK test if no previous report is available.
- Patients without brain metastasis or with asymptomatic brain metastases (no need for intervention or stable more than 4 weeks after treated).
Adequate organ function within 10 days prior to the study of treatment as defined in the below:
Hepatic function
Total serum bilirubin (TBIL) ≤ 1.5 times upper limit of normal (ULN); Aspartate transaminase (AST), alanine transaminase (ALT) and γ- glutamyltransferase (GGT) ≤ 2.5 times ULN if no demonstrable liver metastases, or otherwise ≤ 5 times ULN.
Bone marrow function
Absolute neutrophil count (ANC) ≥ 1.5 x 10⁹/L; Platelets (PLT) count ≥ 100 x 10⁹/L; Hemoglobin (Hb) ≥ 90 g/L.
Renal function
Creatinine clearance ≥ 60 mL/min.
Pancreatic function
Serum total amylase ≤1.5 times ULN; Serum lipase ≤ 1.5 times ULN.
Blood glucose
Fasting Blood Glucose (FBG) ≤ 200 mg/dL (11.1 mmol/L).
Serum lipid
Serum cholesterol ≤ 500 mg/dL (12.92 mmol/L).
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50%.
- Any toxicity of previous antineoplastic treatments was restored to ≤ 1 (except hair loss).
- Female patients with reproductive potential must have a negative serum pregnancy test, male and female patients of childbearing potential must be willing to completely abstain or agree to use an appropriate method of contraception during the entire study duration and for at least 3 months after the last dose of study medication.
- Willingness and ability to give informed consent and follow protocol procedures, and comply with follow-up visit requirements.
Exclusion Criteria:
- Any of the following within 6 months prior to starting trial treatment: Cerebrovascular accident/ stroke, myocardial infarction, severe/ unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), second- or third- degree atrioventricular (AV) block (unless paced) or any AV block with PR interval >220 msec, or any grade of uncontrolled atrial fibrillation.
- ECG evaluated QT interval corrected (Fridericia) (QTcF) of > 450 msec in males or > 470 msec in females or congenital long QT syndrome.
- Grade ≥ 3 peripheral neuropathy (CTCAE version 5.0).
- Any active autoimmune diseases or history of autoimmune diseases that require long-term steroid or other immunosuppressants treatment.
- Previous medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
- Patients being treated with any anticoagulants, prone to bleeding, or have a coagulation disorder.
- Active hepatitis (Hepatitis B: HBsAg-positive and HBV-DNA ≥ 2000 IU/ mL; Hepatitis B: HCV antibody-positive and HCV-RNA ≥ 1000 IU/ml), HIV antibody-positive; Active syphilis.
- Patient underwent major surgery within 4 weeks prior to starting trial treatment.
- Patients received radical radiotherapy within 4 weeks, palliative radiotherapy within 2 weeks, or radioactive agents (strontium, samarium, etc.) within 8 weeks prior to starting trial treatment.
- Patients received systemic antitumor therapy, including chemotherapy, immunotherapy, biotherapy (cancer vaccine, cytokine or cancer growth control factor), or clearly indicated antitumor traditional Chinese medicine within 4 weeks (targeted therapy within 2 weeks) prior to starting trial treatment.
- Patients treated with the following drugs and could not be discontinued at least 7 days prior to starting trial treatment and during the entire study duration: drugs known to be strong inducers or suppressors of CYP3A (for details, see prohibited combination drugs in this trial).
- Patients with any active infection requiring systemic therapy within 4 weeks prior to starting trial treatment.
- Comorbidities that may seriously endanger the patient's safety or affect the completion of the trial, such as severe diabetes, according to the judgment of investigator.
- A clear previous history of neurological or psychiatric disorders, including dementia or diagnosed epilepsy for any reason.
- With a history (within 5 years) or presence of other malignancies, excluding cured skin basal cell carcinoma and carcinoma in situ of the cervix.
- Other situations that may increase the risks related to the study medication, interfere with the interpretation of the study results, affect compliance of the trial, etc. are determined by the investigator to be not suitable for the trial.
- In phase II: previously received third-generation ALK TKIs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Phase I/II Study of SY-3505
SY-3505 will be given orally in ascending doses (escalation cohort), until the DLT or RP2D is reached.
Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose.
In phase II, SY-3505 will be given at RP2D in advanced ALK-positive NSCLC patients.
|
The third-generation ALK TKI
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Incidence rate of dose limiting toxicities (DLTs) during the first cycle of treatment
Time Frame: Dose-escalation Cycle 1 (each cycle is 28 days)
|
Maximum Tolerated Dose(s) (MTD(s)) and/or recommended phase 2 dose (RP2D(s)) in Cycle 1.
|
Dose-escalation Cycle 1 (each cycle is 28 days)
|
Phase I: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability
|
Up to 24 months
|
Phase II: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-3505
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase I: Overall Response Rate (ORR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-3505
|
Up to 24 months
|
Phase I & II: Disease control rate (DCR) as assessed by RECIST 1.1 criteria
Time Frame: Up to 24 months
|
Preliminary anti-tumor activity of SY-3505
|
Up to 24 months
|
Phase I & II: Duration of response (DOR)
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-3505
|
Up to 24 months
|
Phase I & II: Progression-free survival (PFS)
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-3505
|
Up to 24 months
|
Phase I & II: Overall survival (OS)
Time Frame: Up to 24 months
|
Anti-tumor activity of SY-3505
|
Up to 24 months
|
Phase I & II: Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: Up to 24 months
|
Characterization of the safety and tolerability
|
Up to 24 months
|
Phase I & II: Pharmacokinetics (Cmax) for SY-3505
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Defined as maximum observed plasma concentration
|
Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Phase I & II: Pharmacokinetics (Tmax) for SY-3505
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Defined as time to maximum plasma concentration
|
Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Phase I & II: Pharmacokinetics (AUC0-t) for SY-3505
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Defined as area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration
|
Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Phase I & II: Pharmacokinetics (t½) for SY-3505
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Defined as the apparent plasma terminal phase disposition half-life
|
Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Phase I & II: Pharmacokinetics (Cl/F) for SY-3505
Time Frame: Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Defined as oral dose clearance
|
Protocol-defined time points during Cycles 1 and 2 of treatment (each cycle is 28 days)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SY-3505-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on SY-3505
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-small-cell Lung CarcinomaChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDNot yet recruitingNon-small Cell Lung CancerChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid CancerChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingNon-Small Cell Lung CancerChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruitingAdvanced Solid TumorChina
-
Shouyao Holdings (Beijing) Co. LTDRecruiting
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Completed